RoosterBio Inc. Announces Winners of 2020 hMSC Development Grants
Share Article
Each awardee will receive up to $12,000 in requested RoosterBio’s hMSC and bioprocess media products
We are very pleased to support hMSC-based methods and applications in Genetic Engineering by enabling a rapid and efficient path to generate key cellular raw materials and scale up manufacturing, leading to shortened timelines on research and clinical translation. - RoosterBio CEO Margot Connor FREDERICK, Md. (PRWEB) March 11, 2021 RoosterBio, a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems, announced the 2020 Winners of our RoosterBio Development Award. This program empowers investigators who share our common goals in emerging applications of hMSCs and supports their supply chain industrialization for regenerative medicine’s next generation of clinical breakthroughs.
RoosterBio Partners with Sartorius to Advance Cell and Gene Therapy Manufacturing
RoosterBio s innovative hMSCs and bioprocess media systems, coupled with Sartorius s scalable closed system bioreactor, downstream processing, and analytics, offers end-to-end hMSC manufacturing solutions for the field of regenerative medicine.
FREDERICK, Md., Jan. 14, 2021 (GLOBE NEWSWIRE) RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks, highly engineered media and hMSC bioprocess systems, today announces the signing of a strategic collaboration with Sartorius, a leading international partner of life science research and the biopharmaceutical industry. The collaboration aims to advance the scale-up of hMSC manufacturing for regenerative medicine by leveraging the best-in-class solutions of both companies to significantly reduce process development efforts, industrialize the supply chain and accelerate the development and commercialization of gr